Asset profile
efpeglenatide
Peptide
Evidence outlook · results not reported
AMPLITUDE-M (NCT03353350) · Type 2 Diabetes Mellitus
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
AMPLITUDE-M (NCT03353350): The trial was randomized, quadruple-blinded, placebo-controlled, and included 406 participants, providing a strong comparative design. However, the primary endpoint was the surrogate measure of HbA1c change, and although the reported changes favored efpeglenatide, statistical significance for the primary comparison was not reported.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 24 direct rivals (same mechanism and indication), 26 same-class, 60 same-indication; 34 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Efpeglenatide: this drug | Phase 3 | Peptide | GLP-1 receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CJC-1134-PC | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | ||
| HDG1901 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HSK7653 | Phase 3 | Small molecule | GLP-1 receptor | ||
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
18 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
November 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.